TUESDAY, June 13, 2017 (HealthDay News) -- For patients with type 2 diabetes and high cardiovascular risk, canagliflozin is associated with a lower risk of cardiovascular events, according to a study published online June 12 in the New England Journal of Medicine. The research was published to coincide with the annual meeting of the American Diabetes Association, held from June 9 to 13 in San Diego.
Bruce Neal, M.B., Ch.B., Ph.D., from the George Institute for Global Health at the University of New South Wales in Sydney, and colleagues integrated data from two trials involving 10,142 participants with type 2 diabetes and high cardiovascular risk who were randomized to receive canagliflozin or placebo.
The researchers found that the rate of the primary outcome (composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke) was 26.9 and 31.5 participants per 1,000 patient-years in the canagliflozin and placebo groups, respectively (hazard ratio, 0.86; 95 percent confidence interval, 0.75 to 0.97; P < 0.001 for noninferiority; P = 0.02 for superiority). Based on the prespecified hypothesis, renal outcomes were not viewed as statistically significant; however, with respect to progression of albuminuria and the composite outcome of a sustained 40 percent reduction in the estimated glomerular filtration rate, the need for renal-replacement therapy, or death from renal causes, there was a possible benefit for canagliflozin (hazard ratios, 0.73 [95 percent confidence interval, 0.67 to 0.79] and 0.60 [95 percent confidence interval, 0.47 to 0.77], respectively).
"Patients treated with canagliflozin had a lower risk of cardiovascular events than those who received placebo," the authors write.
The study was funded by Janssen Research and Development, the manufacturer of canagliflozin.
Abstract
Full Text
More Information
